M. Norton

发表

Screening for neurocognitive impairment, depression, and anxiety in HIV-infected patients in Western Europe and Canada

K. Robertson, J. V. van Wyk, J. Molina, 2014, AIDS care.

Changes in lipid levels after 48 weeks of dual versus triple therapy observed in the GARDEL study

J. Gatell, P. Cahn, O. Sued, 2014, Journal of the International AIDS Society.

Neurocognitive impairment, depression, and anxiety in HIV‐1‐infected patients across western Europe and Canada: the CRANIum study ‐ ethnicity analysis

O. Van de Steen, G. Schembri, D. Elbirt, 2012 .

Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial

P. Easterbrook, H. Namata, A. Siika, 2018, The Lancet. Infectious diseases.

Meta-Analysis of the Safety, Tolerability, and Efficacy of Lopinavir/Ritonavir-Containing Antiretroviral Therapy in HIV-1–Infected Women

K. Squires, R. Trinh, L. Fredrick, 2012, HIV clinical trials.

Lopinavir/ritonavir combined with raltegravir or tenofovir/emtricitabine in antiretroviral-naive subjects: 96-week results of the PROGRESS study.

J. Gathe, R. Trinh, T. Podsadecki, 2012, AIDS research and human retroviruses.

Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, EARNEST trial

P. Easterbrook, T. Peto, N. French, 2017, The lancet. HIV.

KAPITAL2: a study of treatment satisfaction reported by patients on lopinavir/r anchored regimens and physicians who provide HIV care

Á. Burgos, E. Cabrero, M. Norton, 2008 .

Pharmacokinetic enhancement in HIV antiretroviral therapy: a comparison of ritonavir and cobicistat.

A. Salem, D. Bow, B. Renjifo, 2015, AIDS reviews.

Barriers to access to care reported by women living with HIV across 27 countries

M. Johnson, M. Loutfy, L. Hocqueloux, 2015, AIDS care.

Long‐term (96‐week) follow‐up of antiretroviral‐naïve HIV‐infected patients treated with first‐line lopinavir/ritonavir monotherapy in the MONARK trial *

F. Raffi, J. Delfraissy, M. Chaix, 2010, HIV medicine.

Protease Inhibitor Resistance Analysis in the MONARK Trial Comparing First-Line Lopinavir-Ritonavir Monotherapy to Lopinavir-Ritonavir plus Zidovudine and Lamivudine Triple Therapy

C. Delaugerre, C. Rouzioux, F. Raffi, 2009, Antimicrobial Agents and Chemotherapy.

Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients

Philippe Flandre, Pierre-Marie Girard, C. Delaugerre, 2008, AIDS.

Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIV

J. Arribas, R. Delgado, M. Pérez-Elías, 2008, AIDS.

HIV Drug Therapy in the Americas Congress, 13 – 15 June 2013, São Paulo, Brazil

M. Lederman, D. Kuritzkes, K. White, 2013, Journal of the International AIDS Society.

Lopinavir/ritonavir monotherapy after virologic failure of first-line antiretroviral therapy in resource-limited settings

D. Katzenstein, J. Crump, J. Bartlett, 2012, AIDS.

International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK

Raúl Tabarés Gutiérrez, Samit R. Joshi, H. Jessen, 2016, Journal of the International AIDS Society.

Effect of Lopinavir/Ritonavir Monotherapy on Quality of Life and Self-Reported Symptoms among Antiretroviral-Naive Patients: Results of the MONARK Trial

F. Raffi, B. Spire, J. Delfraissy, 2008, Antiviral therapy.

A Pilot Study of Switch to Lopinavir/Ritonavir (LPV/r) Monotherapy from Nonnucleoside Reverse Transcriptase Inhibitor–Based Therapy

J. Shearer, M. Norton, G. Pierone, 2006, HIV clinical trials.

Monotherapy with Lopinavir/Ritonavir as Maintenance After HIV-1 Viral Suppression: Results of a 96-Week Randomized, Controlled, Open-Label, Pilot Trial (KalMo Study)

M. Schechter, J. C. Faulhaber, J. Pilotto, 2009, HIV clinical trials.

Maternal and foetal outcomes among 4118 women with HIV infection treated with lopinavir/ritonavir during pregnancy: analysis of population-based surveillance data from the national study of HIV in pregnancy and childhood in the United Kingdom and Ireland

C. Thorne, P. Tookey, M. Norton, 2015, BMC Infectious Diseases.

International Congress of Drug Therapy in HIV Infection 2‐6 November 2014, Glasgow, UK

Samit R. Joshi, Charlene A Flash, Thomas Lengauer, 2014 .

Prospective one-year bone loss in treatment-naïve HIV+ men and women on single or multiple drug HIV therapies.

C. Roux, K. Briot, J. Delfraissy, 2011, Bone.

Prevalence, Mutation Patterns, and Effects on Protease Inhibitor Susceptibility of the L76V Mutation in HIV-1 Protease

D. Kempf, N. Parkin, T. Pilot‐Matias, 2010, Antimicrobial Agents and Chemotherapy.

Safety and Effectiveness of Palivizumab in Children at High Risk of Serious Disease Due to Respiratory Syncytial Virus Infection: A Systematic Review

Doris Makari, K. Unnebrink, G. Notario, 2014, Infectious Diseases and Therapy.

Drug susceptibility and resistance mutations after first-line failure in resource limited settings.

D. Katzenstein, J. Bartlett, W. Stevens, 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Safety and efficacy of lopinavir/ritonavir-containing antiretroviral therapy in patients aged <50 versus ≥50 years from randomized trials

J. Wyk, M. Fisher, L. Fredrick, 2014 .

Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the randomised, open label, non-inferiority GARDEL trial.

J. Gatell, P. Cahn, O. Sued, 2014, The Lancet. Infectious diseases.

Intramuscular depot formulations of leuprolide acetate suppress testosterone levels below a 20 ng/dL threshold: a retrospective analysis of two Phase III studies

A. Soliman, M. Gittelman, L. Karsh, 2016, Research and reports in urology.

Evolution of Protease Inhibitor Resistance in Human Immunodeficiency Virus Type 1 Infected Patients Failing Protease Inhibitor Monotherapy as Second-line Therapy in Low-income Countries: An Observational Analysis Within the EARNEST Randomized Trial

P. Easterbrook, N. French, H. Namata, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Lopinavir/Ritonavir Monotherapy as Second-line Antiretroviral Treatment in Resource-Limited Settings: Week 104 Analysis of AIDS Clinical Trials Group (ACTG) A5230.

D. Katzenstein, J. Crump, J. Bartlett, 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Comparison of renal changes with lopinavir/ritonavir plus raltegravir or tenofovir/emtricitabine in the PROGRESS study

C. Argyropoulos, L. Cotte, J. Gathe, 2014 .

Diarrhea Associated with Lopinavir/Ritonavir-Based Therapy

L. Fredrick, M. Norton, W. Woodward, 2012, Journal of the International Association of Physicians in AIDS Care.

Fat tissue distribution changes in HIV-infected patients treated with lopinavir/ritonavir. Results of the MONARK trial.

P. Morlat, C. Roux, K. Briot, 2011, Current HIV research.

Prevalence, Mutation Patterns, and Effects on Protease Inhibitor Susceptibility of the L76V Mutation in HIV-1 Protease

D. Kempf, N. Parkin, E. Stawiski, 2010, Antimicrobial Agents and Chemotherapy.

Evaluation of myocardial infarction and coronary artery disease in subjects taking lopinavir/ritonavir: a study using clinical trial and pharmacovigilance databases.

M. Patwardhan, W. Zachry, A. Nilius, 2012, International journal of clinical pharmacology and therapeutics.

Diarrhea Associated with Lopinavir/Ritonavir-Based Therapy

L. Fredrick, M. Norton, W. Woodward, 2012, Journal of the International Association of Physicians in AIDS Care.